Generic drugs manufactured in India are linked to significantly more "severe adverse events" for patients who use them than equivalent drugs produced in the United States, a new study finds.
India’s Contract Research, Development, and Manufacturing Organization industry is set to double to US$ 14 billion by 2028, driven by pharma outsourcing, regulatory support, and global supply chain ...
A new study reveals that generic drugs manufactured in India have a higher association with severe adverse events such as ...
The U.S. Senate confirmed Robert F. Kennedy Jr. as the Secretary of the Department of Health and Human Services on ...
Union Minister JP Nadda announced the launch of the National Mass Drug Administration Round in 13 states to eliminate ...